or Try an Advanced Search...

    Technical Analysis for TSHA - Taysha Gene Therapies, Inc.

    Grade Last Price % Change Price Change
    F 1.44 5.11% 0.07
    TSHA closed up 5.11 percent on Thursday, November 7, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Nov 12
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical TSHA trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Bullish Engulfing Bullish 5.11%
    Volume Surge Other 5.11%
    Lower Bollinger Band Walk Weakness 5.11%
    Wide Bands Range Expansion 5.11%
    Lower Bollinger Band Touch Weakness 5.11%
    Older End-of-Day Signals for TSHA ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 7 hours ago
    2x Volume Pace about 7 hours ago
    1.5x Volume Pace about 7 hours ago
    3x Volume Pace about 7 hours ago
    Up 5% about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    TSHA Chart by TradingView
    Basic chart:

    Profile

    Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Rare Diseases Gene Therapy Lipid Storage Disorders Monogenic Deficiency Monogenic Diseases Gangliosidosis Gm2 Gangliosidoses Gm2 Gangliosidosis

    Is TSHA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 6 Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13
    Oct 22 Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
    Oct 16 Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds?
    Oct 14 Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why
    Oct 14 Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data
    Oct 3 Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5?
    Sep 26 Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress
    Sep 19 Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?
    Aug 18 Taysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
    Aug 12 Taysha Gene Therapies GAAP EPS of -$0.09 beats by $0.01, revenue of $1.12M misses by $1.51M
    See more TSHA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.32
    52 Week Low 1.19
    Average Volume 2,298,766
    200-Day Moving Average 2.39
    50-Day Moving Average 1.99
    20-Day Moving Average 1.82
    10-Day Moving Average 1.64
    Average True Range 0.12
    RSI (14) 29.08
    ADX 31.7
    +DI 12.46
    -DI 41.27
    Chandelier Exit (Long, 3 ATRs) 1.70
    Chandelier Exit (Short, 3 ATRs) 1.56
    Upper Bollinger Bands 2.34
    Lower Bollinger Band 1.29
    Percent B (%b) 0.14
    BandWidth 57.77
    MACD Line -0.18
    MACD Signal Line -0.12
    MACD Histogram -0.0585
    Fundamentals Value
    Market Cap 269.22 Million
    Num Shares 187 Million
    EPS -2.87
    Price-to-Earnings (P/E) Ratio -0.50
    Price-to-Sales 23.26
    Price-to-Book 5.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.62
    Resistance 3 (R3) 1.61 1.54 1.59
    Resistance 2 (R2) 1.54 1.49 1.54 1.58
    Resistance 1 (R1) 1.49 1.47 1.51 1.50 1.57
    Pivot Point 1.42 1.42 1.43 1.42 1.42
    Support 1 (S1) 1.37 1.37 1.40 1.38 1.31
    Support 2 (S2) 1.30 1.35 1.31 1.30
    Support 3 (S3) 1.25 1.30 1.29
    Support 4 (S4) 1.26